Apixaban and Danaparoid: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Danaparoid
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines thin your blood. Apixaban (Eliquis) and danaparoid each work to stop clots, but through slightly different routes. When you take them together, their blood-thinning effects add up, which means a higher chance of bleeding. That bleeding can sometimes be serious.
Watch for warning signs like unusual bruising, pink or red urine, black or bloody stools, nosebleeds that won't stop, or bleeding gums. If you notice heavy bleeding or feel dizzy or weak, get emergency help right away. The good news: your care team can manage this by monitoring you closely, and a reversal agent exists if it's ever needed. Keep taking both exactly as prescribed unless your doctor tells you otherwise.
Mechanism: Additive anticoagulation. Both apixaban (direct factor Xa inhibitor) and danaparoid (heparinoid with predominant anti-Xa activity) suppress factor Xa, producing an additive pharmacodynamic effect and increased bleeding risk. Neither is a prodrug.
- Direction/magnitude: Increased anti-Xa activity and bleeding risk; a 50 to 60% rise in anti-Xa activity was seen with apixaban plus enoxaparin as a comparator.
- Evidence: Probable. Severity: major.
- Management: Avoid overlap unless clinically justified. Monitor for bleeding; discontinue apixaban if active pathological bleeding occurs. Apixaban's PD effect persists at least 24 hours post-dose. A specific reversal agent is available; PCC, aPCC, or rFVIIa may be considered.
What happens
An increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
When apixaban, an inhibitor of factor Xa, is given together with another anticoagulant, the likelihood of bleeding rises. Pharmacodynamic drug interaction studies of apixaban demonstrated that giving apixaban alongside enoxaparin produced a 50% to 60% rise in anti-factor Xa activity. If active pathological bleeding develops, apixaban should be stopped. There is an agent available that reverses the anti-factor Xa activity of apixaban. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the final dose. Patients should be told about the signs and symptoms of blood loss and instructed to report them without delay or to proceed to an emergency room. Prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa may be considered as options. If PCCs are administered, it is neither useful nor recommended to monitor apixaban's anticoagulation effect through a clotting test (PT, INR, or aPTT) or through anti-factor Xa (FXa) activity. Absorption of apixaban is reduced by activated oral charcoal, which consequently decreases apixaban exposure1.
Why it happens (mechanism)
Additive anticoagulation
How to manage this interaction
Keep taking both medicines exactly as prescribed unless your prescriber tells you to change something. This combination raises bleeding risk, so your care team will manage it carefully.
- Your team may monitor you more closely and individualize your treatment.
- Learn the signs of bleeding: unusual bruising, blood in urine or stool, black stools, prolonged nosebleeds, coughing or vomiting blood, severe headache, or feeling faint.
- Report any bleeding right away, or go to an emergency room if it is heavy or won't stop.
- A reversal agent for apixaban exists, and its effect can last at least 24 hours after the last dose.
Ask your pharmacist or doctor any time you're unsure about your two blood thinners.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In investigations examining pharmacodynamic drug interactions involving apixaban, an increase of 50% to 60% in anti-factor Xa activity was noted when apixaban and enoxaparin were given together 1.
Common questions
Can I take Apixaban and Danaparoid together?
Taking apixaban and danaparoid together adds up their blood-thinning effects and raises the risk of serious bleeding, so watch for any signs of bleeding and get medical help immediately if they occur. Keep taking both as prescribed while your care team monitors you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Danaparoid interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Danaparoid interaction managed?
Keep taking both medicines exactly as prescribed unless your prescriber tells you to change something. This combination raises bleeding risk, so your care team will manage it carefully. Your team may monitor you more closely and individualize your treatment. Learn the signs of bleeding: unusual bruising, blood in urine or stool, black stools, prolonged nosebleeds, coughing or vomiting blood, sever… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Danaparoid need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Apixaban
Keep reading about Danaparoid
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist